| Lundbeck (Schweiz) AG - Abilify Maintena 400 mg, Depot-Injektionssuspension |
| 63177 | | 02 | | Abilify Maintena 400 mg | | Depot-Injektionssuspension | | N05AX12 | | Aripiprazol | | 28.04.2014 | | |
|
| Composition |
| Praeparatio cryodesiccata: aripiprazolum 400 mg ut aripiprazolum monohydricum, carmellosum natricum, mannitolum, natrii dihydrogenophosphas monohydricus, natrii hydroxidum, pro vitro corresp. natrium max. 2.2 mg.
Solvens (i.m.): aqua ad iniectabile pro vitro.
Corresp. in solutione recenter reconstituta 200 mg pro 1 mL. |
| Packungsbestandteile |
| in solutione recenter reconstituta 200 mg pro 1 mL | | | |
| in solutione recenter reconstituta 200 mg pro 1 mL | | | |
| Praeparatio cryodesiccata: | | Depot-Injektionssuspension | | | | | | Principe actif | Concentr. |
|---|
| Aripiprazole | 400 mg |
| | | | Agents auxilliaires |
|---|
| Carmellose Sodique | | Mannitol | | Sodium Dihydrogenophosphate Monohydrate | | Sodium Hydroxide |
|
|
| numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 004 | Flacon perforable à 400 mg | DDP | DDP | B | | Oui |
|
